The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The ...

Studies show that smell loss with age may reflect more serious underlying problems, and is even linked to how long we're ...

Lyra Therapeutics is abandoning work on its rhinosinusitis treatment and laying off its remaining employees.

Abstract: Colorectal cancer has become a significant global health challenge and causes millions of fatalities every year. A key factor contributing to its high fatality rate is the absence of timely ...

Abstract: Colon polyps in colonoscopy images exhibit significant differences in color, size, shape, appearance, and location, posing significant challenges to accurate polyp segmentation. In this ...

We are grateful for the contributions of our employees most of whom will leave Lyra as a result of this decision to discontinue development of LYR-210. Our priority moving forward is to evaluate and ...

A new add-on therapy administered every six months targets key inflammatory pathways in asthma and chronic rhinosinusitis ...

Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...

Early launch numbers of Brinsupri are so strong that Insmed couldn’t wait for the J.P. Morgan Healthcare Conference to share ...

Although most cases of nosebleeding are simple and not worrying, they should not occur if everything inside the nose is intact, according to Dr. Patricia Loftus ...

GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...